Sphingolipids are unique lipids that serve numerous functions important in cell regulation. Some categories of sphingolipids have also been implicated in the mechanism of action of cancer chemotherapeutic drugs, with the hypothesis being that these drugs are effective because they alter sphingolipid metabolic pathways to increase the production of ceramide, a sphingolipid known to induce cell death. Fenretinide (4-hydroxyphenylretinamide, 4HPR) is one such drug and has been thought to induce apoptosis through an increase of ceramide biosynthesis. However, recent research by W. Zheng et.al 2006., has shown that fenretinide instead increases dihydroceramide, which has traditionally been regarded as innocuous in cell signaling. This study has explored how fenretinide induces cell death via elevation of dihydroceramide and has discovered that dihydroceramide and fenretinide are both potent inducers of autophagy, a pathway for turnover of cell constituents that can also trigger type II programmed cell death. In addition, this analysis has found that after dihydroceramide induces the formation of autophagosomes, it seems to be further metabolized to sphinganine and sphinganine 1-phosphate as indicated by an increase in the quantity of these species and whether or not this results in cell death depends on the balance between these highly bioactive toxic (sphinganine) versus anti-apoptotic (sphinganine-1-phosphate) compounds. Thus, these studies suggest that the mechanism of fenretinide toxicity has many components: Fluke 2 elevation of dihydroceramide to induce autophagy as well as changes in sphinganine and sphinganine-1-phosphate, with the balance between the latter dictating if the autophagy is lethal.
Introduction
In order to understand the mechanism of fenretinide toxicity presented, the following key concepts will first be discussed: i) sphingolipids, ii) role of sphingolipids in regulating cell proliferation and cell death, iii) autophagy, iv) current opinions on autophagic cell death, and v) role of sphingolipids in autophagy..
Sphingolipids -Sphingolipids are a family of phospho-and glycolipids found in
all eukaryotic and some prokaryotic organisms. They are comprised of a sphingoid base backbone that may be unmodified, N-acylated, N-methylated, phosphorylated, or incorporated into more complex sphingolipids, such as ceramide phosphoinositols (yeast), ceramide phosphoethanolamines (insects), and ceramide phosphocholines (mammals and other organisms) as well as simple to complex glycosphingolipids ( Figure   1 ). The biophysical and biochemical properties of this backbone differentiate sphingolipids from other lipid species. For example, at a neutral pH the sphingoid backbone carries a net positive charge, which is rare among membrane lipids (1) . This property may be used to explain the relative ease with which sphingoid bases move among membrane bilayers, allowing them to influence many aspects of both intracellular and extracellular signaling (2) . palmitoyltransferase to yield 3-ketosphinganine. 3-ketosphinganine reductase then reduces 3-ketosphinganine to sphinganine, which is subsequently N-acylated by (dihydro)ceramide synthase yielding dihydroceramide (4) . At this point, dihydroceramide desaturase introduces a 4,5 trans double bond into dihydroceramide forming ceramide (5) . These steps take place on the cytosolic face of the ER (5, 6) . The Fluke 4 resulting ceramide can then be transported to the cis Golgi for incorporation into more complex sphingolipids (7) .
Figure 1 also displays that this biosynthetic pathway has enzymes that function in both the synthesis and turnover pathways. Ceramidases, found in the organelles such as the lysosome and the mitochondria, could perform the reverse reaction of ceramide synthase and deacylate ceramide to form sphingosine (7) . One such enzyme that is found in the lysosome is acid ceramidase; it not only converts ceramide to sphingosine in the biosynthetic pathway, but can also form sphinganine through the turnover of dihydroceramide (1, 3) . These backbone species, sphingosine and sphinganine may then be phosphorylated by sphingosine kinase to yield sphingosine-or sphinganine-1 phosphate, respectively. This complex metabolic pathway profoundly affects the cell, as changes in the natural rheostat of sphingolipid subspecies may serve as a determining factor in cell fate decisions.
Bioactive Sphingolipids -A delicate balance exists between the bioactive sphingolipids that activate cell survival and cell death pathways. Because new roles for sphingolipids are continuously being discovered, there is still much to be learned about how sphingolipids regulate many processes that occur within the cell. Traditionally, ceramide, sphinganine, and sphingosine have been considered to be the bioactive sphingolipids that induce cell death and growth arrest, while sphingosine-and sphinganine-1-phosphate have been regarded as inducers of cell survival and cell proliferation (2, 8) .
Sphingoid bases, sphingosine and sphinganine, are known to activate many signaling pathways that are cytotoxic to cells (2, (9) (10) (11) . Their ability to behave as Fluke 5 detergents when trapped in acidic vesicles allows them to induce cell death by acting as lysosomotrophic agents, which permeabilize the lysosomal membrane allowing lysosomal contents, such as proteases, to be released into the cytosol. These proteases inturn serve as upstream activators of well-characterized cell death pathways (12) .
Although sphinganine and sphingosine are cytotoxic to cells, when phosphorlyated by sphingosine kinase, they form sphinganine-or sphingosine-1 phosphate respectively, and these phosphorylated species promote cell proliferation rather than cell death (2,13).
Ceramide, one of the most widely studied sphingolipids, is a known inducer of apoptosis, type I programmed cell death. (8) . Furthermore, the mechanism of action of certain chemotherapeutic drugs is hypothesized to result from alterations in the normal sphingolipid metabolic pathway to increase the biosynthesis of ceramide within the cell, which in turn results in apoptosis. Fenretinide, a chemotherapeutic agent currently in clinical trials for breast and many other types of cancers, is one such drug (14) .
Fenretinide is thought to increase ceramide by the coordinate activation of serine palmitoyltransferase and ceramide synthase (15, 16) . A second proposed mechanism for fenretinide's mode of action is thought to involve the production of reactive oxygen species (ROS), again resulting in the stimulation of the apoptotic pathway (17) .
However, in previous studies to determine the effect of fenretinide on the de novo sphingolipid biosynthetic pathway, it was found that MCF7 breast cancer cells treated with fenretinide experienced only a nominal change in ceramide production; whereas, dihydroceramide production increased as much as 10-fold, both as the free species and as the backbone for dihydroceramide metabolites (2) . The distinction between ceramides and dihydroceramides was possibly overlooked in previously published studies because Fluke 6 ceramide analysis was performed by techniques such as thin layer chromatography (TLC) or diacylglycerol kinase assays (DGK), and these techniques cannot readily distinguish dihydroceramides from ceramides. The mechanism of dihydroceramide accumulation has been investigated and appears to be due to the inhibition of dihydroceramide desaturase (2) . This finding is significant because dihydroceramide has long been considered to be inactive in cell signaling (18) . However, the ability of chemopreventive agents, such as fenretinide, to induce increases in dihydroceramide leads one to question the bioactive status of this molecule. Furthermore, this research identifies a previously uncharacterized signaling function for dihydroceramide, the induction of the formation of cytoplasmic vacuoles called autophagosomes.
Autophagy -Translated from the Greek meaning "to eat oneself," autophagy is an intracellular degradation and recycling pathway that is in various forms ubiquitous throughout eukaryotic cells. Macroautophagy, which will be referred to as autophagy for the remainder of this thesis, allows cells to degrade cytoplasmic organelles and proteins to produce amino acids, lipids, sugars, and nucleotides during nutrient poor conditions (19, 20) . Autophagy also provides a way for cells to degrade damaged organelles, thus helping cells survive in otherwise cytotoxic situations (21) . In recent years mechanisms for monitoring the dynamic process of autophagy have provided evidence that this cell survival pathway can also result in programmed cell death, which will be discussed in more depth in the following section (22) (23) (24) . (25) As seen in Figure 2 , autophagy is usually triggered by one of the following events: nutrient starvation (26) , bacterial or viral invasion (27, 28) , or certain anticancer drugs (29) (30) (31) . Autophagy is mediated by a wide number of signaling pathways, and as technologies for monitoring and understading autophagy improve, many more are being elucidated (20) . Autophagy begins with the isolation of a piece of the endoplasmic reticulum or a membrane created from de novo synthesis. This isolated double membrane elongates and recruits microtubules-associated protein light chain 3 (LC3) to its surface as it surrounds proteins and organelles to be degraded forming the autophagosome. The autophagosome subsequently fuses with the lysosome to form the autophagolysosome, Fluke 8 whose acidic environment allows for the degradation of the sequestered proteins and organelles (25) .
Autophagy and Cell Death -Autophagy is a complex process; in some cases autophagy serves a protective role, but in other situations autophagy can result in cell death. Autophagic cell death, referred to as type II programmed cell death, is distinct from apoptosis, type I cell death, and necrosis, type III cell death. Degradation of organelles is one of the first events to occur during autophagy, while the cytoskeleton is one of the last items degraded prior to cell death. Whereas, during apoptosis, the cytoskeleton collapses almost immediately following induction and the organelles are among the last items degraded prior to cell death. Furthermore, necrotic death is characterized by an inflammatory response, not present in either autophagy or apoptosis (22) . However, the distinction between autophagic cell death and apoptotic cell death is not always so distinct. There are many shared molecular signaling pathways activated during both autophagic and apoptotic cell death (20, 32) .
Currently a debate exists over autophagy's connection to cell death, with questions surrounding the idea of whether autophagy alone induces cell death or whether cell death processes, like apoptosis, play a role in autophagic cell death. Some believe that autophagy triggers apoptosis, while others believe that autophagy and apoptosis can occur simultaneously inside a cell (19) (20) (21) (22) 25) . In a recent review, Yoshimori Many studies have elegantly established ceramide's ability to mediate autophagy through the activation of several key molecules. Ceramide induces lethal autophagy through the activation of BNIP3, a mitochondrial death associated protein that induces autophagy (34) . Ceramide also activates lethal autophagy by upregulating beclin1, a gene that is necessary for autophagy to occur in cells (29, 34) . Another sphingolipid mediator of autophagy, sphingosine-1-phosphate induces protective autophagy in MCF7 breast Cell Lines -MCF7 cells were obtained from the ATCC (Manassas, VA) and cultured at 37° C in 5% CO 2 in Minimal Essential Media (MEM) supplemented with 10% FBS, 100x nonessential amino acids (0.01%), sodium bicarbonate (1.5 mg/mL), and bovine insulin (0.01 mg/mL).
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Methods to Measure Autophagy -LC3 (microtubule-associated protein light chain 3) is normally diffusely distributed throughout the cytoplasm, but upon induction of autophagy is recruited to the autophagosomal membrane and appears in a punctate pattern. When LC3 is tagged with a fluorescent protein, its localization, in the cytoplasm or as a part of the autophagosome, can be easily monitored using confocal microscopy.
For our studies, GFP-LC3 localization was monitored as previously described (23, 26) . 
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Taken together, these results suggest that 4HPR-mediated autophagy may be dependent on intracellular increases in dihydroceramide (2) . Therefore, we next investigated whether sphingolipid biosynthesis was necessary for 4HPR-induced autophagy. A. Cells were cultured for autophagy analysis as described in "Experimental Procedures." Twentyfour hours after transfection, cells were pre-treated with ISP1 (1 µM) for 1 hour prior to treatment with 4HPR (10 µM). The punctuate vesicles indicate the presence of autophagosomes. The images shown are representative of multiple independent experiments Images were scored as described in the "Experimental Procedures." B. Cells were for viability analysis as described in 'Experimental Procedures.' MCF7 cells were pre-treated with ISP1 (1 µM) for 1 hour prior to treatment with 4HPR (10 µM). Forty-eight hours after 4HPR treatment, Wst1 reagent was added and colormetric analysis was performed following one-hour incubation at 37ºC. All measurements have been normalized to control cells.
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Dihydroceramide turnover in the autophagolysosome contributes to fenretinide cytotoxicity.-After fenretinide induced dihydroceramide accumulation mediates the formation of autophagosomes, dihydroceramide seems to be further metabolized to sphinganine and sphinganine 1-phosphate, as indicated by an increase in the quantity of these species in a previous study (2) . The cytotoxicity of 4HPR is hypothesized to depend on the balance between these highly bioactive toxic (sphinganine) versus anti-apoptotic (sphinganine-1-phosphate) compounds.
Sphinganine may be produced from the hydrolysis of the accumulated dihydroceramide by acid ceramidase within the autophagolysosome, which presumably acquired lysosomal sphingolipids hydrolases upon autophagosomal and lysosomal fusion (37) . Since sphinganine is known to be a toxic, lysosmotrophic agent (11, 12) , accumulation of this sphingoid base should result in 4HPR cytotoxicity or lethal autophagy. Furthermore, if sphinganine accumulation is due to the turnover of dihydroceramide rather than de novo synthesis and if sphinganine is involved in 4HPR cytotoxicity, then suppression of acid ceramidase should decrease the cytotoxicity of 4HPR.
In order to investigate this idea, MCF7 cells were transfected with acid ceramidase siRNA to suppress acid ceramidase activity prior to 4HPR treatment, and cell viability was assessed. Figure 6 ). These results suggest that the sphinganine accumulation observed in a previous study is indeed due to the turnover of dihydroceramide, which inturn contributes to the cytotoxic mechanism of 4HPR. Cells were cultured for cell viability as described in "Experimental Procedures." MCF7 cells were transfected with acid ceramidase (AC) siRNA 24 hours later. 24 hours after transfection cells were treated with 10µM fenretinide. 48 hours after fenreitnide treatment and 72 hours after AC siRNA Wst1 reagent was added and colormetric analysis was performed following one hour incubation at 37ºC. All measurements have been normalized to control cells.
Inhibition of sphingosine kinase increases fenretinide cytotoxicity -A portion of
the sphinganine produced from dihydroceramide turnover, described above, will presumably efflux from the autophagolysosome in a manner analogous to the lysosomal degradation of sphingolipids (2) . Once effluxed, a portion of this sphinganine will become phosphorylated by sphingosine kinase to yield sphinganine 1-phosphate (13),
owing to the accumulation of this species as noted in a previous study (2) . In order to investigate this idea, dimethylsphingosine (DMS) was used to inhibit sphingosine kinase (38) . MCF7 cells treated with 4HPR (10 µM, 48 hours) or DMS (1 µM and 2.5 µM, 48 hours) alone experienced an approximate 35% decrease in cell viability when compared to control cells (Figure 7) . However, when MCF7 cells were pre-treated with DMS for 1 hour prior to 4HPR treatment, a more rapid, pronounced decrease in cell viability was observed, resulting in a 59% and a 77% decrease in cell viability following 1 µM and 2.5 µM DMS pre-treatments respectively ( Figure 7 ). These results suggest that as sphingosine kinase is inhibited, protective autophagy may also be inhibited and result in a 4HPR induced lethal autophagic death. Cells were cultured for cell viability as described in 'Experimental Procedures.' Cells were treated with 4HPR (10 µM) alone, dimethlysphingsone (DMS) alone (1 µM or 2.5 µM) or pre-treated with DMS (1 µM or 2.5 µM) for one hour prior to treatment with 4HPR (10µM). 48 hours after 4HPR treatment Wst1 reagent was added and colormetric analysis was performed following one hour incubation at 37ºC. All measurements have been normalized to control cells.
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Discussion
Fenretinide is a promising anti-cancer agent currently in clinical trials.
Furthermore, fenretinide is a known inducer of cell death in many types of cancer cells, but the mechanism of its action was not well understood (39) . Previously published findings have attributed fenretinide's cytotoxicity to the activation of reactive oxygen species and/or increases in ceramide biosynthesis (15) (16) (17) 40) . However, the results 
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In addition to identifying a previously uncharacterized signaling function for dihydroceramide, our study has provided the first evidence of a novel autophagic pathway induced by fenretinide, differing from previous studies which cited fenretinide's cell death mechanism via induction of apoptosis (15) (16) (17) . The idea must not be excluded that fenretinide-induced autophagy may be occurring simultaneously with the apoptosis observed in other studies. However, further evidence is needed to confirm this idea, and we hypothesize that if both do occur as a result of fenretinide treatment that the time scale Additionally, some of the sphinganine produced from the hydrolysis of dihydroceramide will efflux from the autophagolysosome in a manner analogous to the lysosomal recycling mechanism of sphingolipids becoming phosphorylated by sphingosine kinase to yield sphinganine 1-phosphate (13) . This sphinganine 1-phoshate is then thought to stimulate a protective autophagic mechanism within the cell, consistent with a previously published study (35) . Our results in Figure 7 provide further support for this notion displaying that when sphingosine kinase is inhibited by DMS, cell viability decreases much more quickly and to a much larger extent. The results suggest that the prevention of sphinganine 1-phosphate formation blocks the protective autophagic mechanism and promotes the lethal autophagic mechanism by disturbing the delicate ratio of toxic sphinganine to protective sphinganine 1-phoshate. It is our hypothesis that Fluke 23
fenretinide's cytoxicity is not due to the inhibition of sphingosine kinase but rather to insufficient activity of sphingosine kinase to handle the large accumulation of sphinganine resulting from the turnvover of dihydroceramide within the autophagolysosome. Figure 8 provides a summation of the results of this study and our current working model of fenretinide's mechanism of action within the cell.
In conclusion, a myriad of recent hypotheses speculate and predict the relationship between autophagy and cell death (24, 32) . The term lethal autophagy used throughout this paper does not attempt to differentiate between apoptotic and autophagic cell death. In our studies, lethal autophagy simply implies that cells contain It is our working hypothesis that fenretinide induced dihydroceramide accumulation results in the formation of autophagosomes. After formation, the autophagosome fuses with lysosomes where it acquires lysosomal sphingolipid hydrolyases, including acid ceramidase. Presumably, the acid ceramidase (AC) will hydrolyze some of the accumulated dihydroceramide to sphinganine. The sphinganine has two possible fates: 1) It can efflux from the autophagolysosome in a manner analogous to the process that occurs during lysosomal degradation of sphingolipids and become phosphorylated (which could result in protective autophagy through the formation of sphingosine 1-phosphate (35) ), or 2) Sphinganine can accumulate in the autophagolysosome due to insufficient sphingosine kinase activity resulting in autophagolysosomal membrane destabilization because of its known ability to behave as a lysosomotrophic agent (12) , which in turn results in the release of pro-death molecules activating cell death pathways. Fenretinide (4HPR), Dihydroceramide (DHCer), Sphinganine (Sa), Sphinganine-1-Phosphate (SaP).
